Pharmaids Pharmaceuticals Ltd.

BSE: PHARMAID524572ISIN INE117D01018

Healthcare
Pharmaceuticals

Share price

₹29.33+1.25 (+4.45%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹53.90
52W low: ₹25.60
Off 52W high: -45.58%
1M return: -2.72%
3M return: -8.91%
6M return: -1.87%
1Y return: -39.16%
20D avg volume: 3,516
50 DMA: ₹30.04
200 DMA: ₹32.67

Key ratios Consolidated

Market cap: ₹103.44 Cr
Current price: ₹29.33
52W high / low: ₹53.90 / ₹25.60
Face value: ₹10.00
P/E: -23.58
P/B: 2.17
EPS (TTM): ₹-1.24
Book value / share: ₹13.51
ROE: —
ROCE: -20.30%
Operating margin: —
Net margin: —
Debt / equity: 0.44
Net debt: ₹20.78 Cr
Interest cover: -3.67
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 13.9 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	4.12	7.18	5.43	8.61	6.66	4.77	4.71	5.24	4.67	—
	0.05	0.10	0.08	0.22	0.04	0.07	0.01	0.01	0.01	—
	4.17	7.28	5.51	8.83	6.70	4.84	4.72	5.25	4.68	—
	5.96	8.65	9.13	15.47	13.88	10.30	8.72	8.75	8.91	—
	0.99	1.40	1.07	9.84	1.92	1.73	2.04	2.36	2.76	—
	0.53	0.47	0.43	0.45	1.23	10.36	0.99	1.10	0.34	—
	2.47	2.73	3.28	3.18	4.19	4.05	3.25	2.87	2.99	—
	0.60	0.65	0.72	1.08	1.20	1.01	0.48	0.34	0.26	—
	0.49	0.48	0.48	0.47	0.61	0.62	0.64	0.61	0.57	—
	0.78	1.05	2.30	3.20	4.38	2.50	—	0.34	1.31	—
	-1.79	-1.37	-3.62	-6.64	-7.17	-5.46	-4.00	-3.49	-4.22	—
	4.20	-0.09	-0.40	2.99	0.00	0.06	-0.01	-0.07	-0.08	—
	2.42	-1.46	-4.02	-3.66	-7.17	-5.40	-4.01	-3.56	-4.30	—
	0.54	0.37	1.38	-1.13	-1.86	0.60	1.00	1.00	1.18	—
	1.87	-1.08	-2.65	-2.53	-5.32	-4.80	-3.02	-2.56	-3.12	—
	0.63	-0.51	-0.70	-0.70	-1.41	-1.11	-0.55	-0.73	-0.76	—
Key metrics
	3.51	-0.33	-2.82	-2.11	-5.36	-3.77	-2.89	-2.61	-3.47	—
	85.20%	-4.60%	-51.90%	-24.50%	-80.50%	-79.00%	-61.40%	-49.80%	-74.30%	—
	45.40%	-15.00%	-48.80%	-29.40%	-79.90%	-100.60%	-64.10%	-48.90%	-66.80%	—
	—	-1.30%	—	-3.80%	—	-4.80%	—	—	—	—
	-38.10%	50.50%	15.30%	64.30%	42.60%	—	—	—	—	—
	135.20%	77.50%	12.30%	1.20%	-70.50%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	25.34	27.88	19.45	—
	0.45	0.29	0.10	—
	25.79	28.17	19.55	—
	39.21	46.94	36.73	—
	13.30	14.74	8.90	—
	1.88	2.43	12.79	—
	11.66	13.38	13.16	—
	3.05	3.49	2.09	—
	1.92	2.03	2.44	—
	7.33	10.89	6.64	—
	-13.42	-18.77	-17.18	—
	6.70	2.46	-0.10	—
	-6.72	-16.30	-17.28	—
	1.16	-4.73	-3.77	—
	-4.39	-11.57	-13.51	—
	-1.28	-3.31	-3.05	—
Key metrics
	-1.75	-10.78	-12.75	—
	-6.91%	-38.70%	-65.60%	—
	-17.32%	-41.50%	-69.50%	—
	—	-20.30%	-16.70%	—
	18.52%	43.30%	—	—
	—	14.40%	—	—
	—	-8.53	-26.47	—
	—	0.35	1.04	—
	—	0.44	0.64	—
	—	20.78	33.10	—
	—	13.9	-19.0	—
Balance sheet
	—	87.26	119.85	—
	—	10.99	22.31	—
	—	0.13	2.14	—
	—	3.43	3.13	—
	—	0.41	12.18	—
	—	4.39	4.85	—
	—	20.26	44.65	—
	—	2.78	16.32	—
	—	24.01	28.71	—
	—	20.91	35.24	—
	—	9.07	5.06	—
	—	11.84	30.18	—
	—	47.60	55.04	—
Cash flow
	—	-4.06	-13.99	—
	—	23.34	-12.02	—
	—	-19.97	23.36	—
	—	4.47	12.48	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	0.00	2.69	0.83	5.97	1.12	0.13	1.21	0.83	0.17	—
	0.05	0.06	0.06	0.19	0.35	1.01	0.00	0.01	0.00	—
	0.05	2.75	0.89	6.16	1.46	1.14	1.21	0.84	0.17	—
	1.50	4.42	5.13	11.62	7.15	4.92	3.06	2.02	1.94	—
	0.00	0.72	0.33	9.29	0.06	0.03	0.00	—	—	—
	0.00	0.00	0.00	0.00	0.55	9.88	0.80	0.61	0.22	—
	0.69	0.85	1.55	1.60	1.40	1.09	0.87	0.72	0.74	—
	0.57	0.60	0.57	1.02	1.11	2.05	0.07	0.01	0.01	—
	0.06	0.05	0.05	0.06	0.05	0.05	0.05	0.05	0.05	—
	0.18	0.28	1.76	2.43	3.53	1.57	0.01	0.03	0.99	—
	-1.45	-1.67	-4.24	-5.46	-5.69	-3.78	-1.84	-1.19	-1.77	—
	4.20	-0.02	0.00	3.13	0.00	0.00	—	—	—	—
	2.75	-1.69	-4.24	-2.33	-5.69	-3.78	-1.84	-1.19	-1.77	—
	0.61	-0.38	1.13	0.68	1.33	-0.72	0.25	0.18	0.15	—
	2.13	-1.31	-3.11	-1.65	-4.36	-3.06	-1.59	-1.01	-1.62	—
	0.61	-0.37	-0.88	-0.47	-1.24	-0.86	-0.45	-0.29	-0.46	—
Key metrics
	3.38	-1.04	-3.62	-1.25	-4.53	-1.68	-1.72	-1.13	-1.71	—
	—	-38.70%	-436.10%	-20.90%	-404.50%	-1,292.30%	-142.10%	-136.10%	-1,005.90%	—
	—	-48.70%	-374.70%	-27.60%	-389.30%	-2,353.80%	-131.40%	-121.70%	-952.90%	—
	—	-1.60%	—	-1.70%	—	-1.70%	—	—	—	—
	-100.00%	1,969.20%	-31.40%	619.30%	558.80%	—	—	—	—	—
	148.90%	57.20%	-95.60%	-63.40%	-169.10%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	9.49	10.60	2.34	—
	0.36	0.66	1.02	—
	9.85	11.26	3.36	—
	22.67	28.33	11.95	—
	10.34	10.91	0.03	—
	0.00	0.40	11.52	—
	4.69	5.40	3.42	—
	2.76	3.30	2.15	—
	0.22	0.21	0.20	—
	4.65	7.99	4.17	—
	-12.82	-17.06	-8.59	—
	7.31	3.11	0.00	—
	-5.51	-13.95	-8.59	—
	2.04	-3.52	-1.31	—
	-3.94	-10.44	-7.28	—
	-1.11	-2.95	-2.06	—
Key metrics
	-2.53	-10.44	-6.24	—
	-26.66%	-98.50%	-266.70%	—
	-41.52%	-98.50%	-311.10%	—
	—	-15.60%	-6.20%	—
	188.45%	353.00%	—	—
	—	-43.40%	—	—
	—	-6.01	-16.76	—
	—	0.34	1.06	—
	—	0.38	0.62	—
	—	20.34	38.93	—
	—	12.0	-226.1	—
Balance sheet
	—	83.96	118.69	—
	—	5.82	12.68	—
	—	0.11	0.47	—
	—	1.38	0.16	—
	—	0.00	9.77	—
	—	—	2.22	—
	—	7.91	24.18	—
	—	1.03	11.38	—
	—	15.64	15.23	—
	—	20.45	39.40	—
	—	5.54	0.00	—
	—	14.91	39.40	—
	—	53.38	63.79	—
Cash flow
	—	-3.53	-7.72	—
	—	24.53	-18.90	—
	—	-21.36	24.64	—
	—	2.48	9.04	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +188.45%
Profit YoY (TTM): +60.68%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +18.52%
Profit YoY (TTM): +72.04%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 32.99%

Quarter	September 2026	June 2026
Promoter %	32.99%	32.99%

Holder	Type	Holding	Previous	Change
Shankarappa Nagaraja Vinaya Babu	Promoter	28.52%	28.52%	0.00%
SHREEDHARA SHETTY	Public	14.53%	14.53%	0.00%
GOKARAM RAMKRISHNA BALAJI	Public	7.99%	7.99%	0.00%
SMITHA SHETTY SANCHIT SHETTY	Public	7.72%	—	—
Tumkur Trade Center Private Limited	Promoter	4.45%	4.45%	0.00%
VENKATA BHAGI RAO SADHANALA	Public	4.29%	—	—
MAKAM SREEVALLI	Public	2.21%	2.21%	0.00%
VENU MADHAVA KAPARTHY	Public	2.02%	2.03%	-0.01%
VENKATESH MAHENDRA	Public	1.24%	1.24%	0.00%
Kant Rao	Promoter Group	0.02%	0.02%	0.00%
Lalithamma	Promoter Group	0.00%	0.00%	0.00%
Koye Lifesciences Private Limited	Promoter Group	0.00%	0.00%	0.00%
B. Venkatswamy	Promoter	0.00%	0.00%	0.00%
Moki Partners	Promoter Group	0.00%	0.00%	0.00%
Activin Chemicals and Pharmaceuticals Private Limited	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Pharmaids Pharmaceuticals Ltd.	103	29.33	-23.58	-20.30%	+18.52% TTM	+72.04% TTM	-39.16%

Filings & corporate actions

Recent announcements

Newspaper publication regarding Special Window for re-lodgement of transfer request of physical shares15 Oct 2026 · Company Update / Newspaper Publication
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter and half year ended September 30, 2026.13 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation w.r.t Closure of Trading Window25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to the Regulation 30(3) & 30(4) read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015, we hereby inform that the ....16 Sep 2026 · Company Update / General
Voting Results along with the Scrutinizer''s Report of the 37th AGM of the Company held on 11th September 2026 through VC/ OAVM.15 Sep 2026 · AGM/EGM / AGM
Outcome of the 37th Annual General Meeting of the Company held on September 11, 2026 i.e., today at 12 noon through VC/OAVM.11 Sep 2026 · AGM/EGM / AGM
Enclosed copies of Newspaper Advertisement published on August 19, 2026 intimating the Notice of 37th Annual General Meeting of the Company19 Aug 2026 · Company Update / Newspaper Publication
Annual Report18 Aug 2026 · Others / Reg. 34 (1) Annual Report
Notice of 37th AGM and Annual Report18 Aug 2026 · AGM/EGM / AGM
Newspaper publication of unaudited financial results (standalone & consolidated) for the quarter ended June 30, 202614 Aug 2026 · Company Update / Newspaper Publication
Submission of unaudited financial results12 Aug 2026 · Result / Financial Results
Outcome of the Board meeting held today i.e. August 12, 202612 Aug 2026 · Board Meeting / Outcome of Board Meeting
Pharmaids Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....6 Aug 2026 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of the SEBI (Depositaries and Participants) Regulations, 2018 for the quarter ended June 30, 2026.7 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Appointment of M/s. V Mahendra & Associates, as the Internal Auditors of the Company for carrying out the Internal Audit for the financial year 2026-27.30 Jun 2026 · Company Update / Change in Management
Intimation w.r.t Closure of Trading Window26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you of the change in Senior Management Personnel ....25 Jun 2026 · Company Update / Change in Management
Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015 - Providing corporate guarantee to subsidiary, Adita Bio Sys Private Limited13 Jun 2026 · Company Update / General
Newspaper publication of Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 202631 May 2026 · Company Update / Newspaper Publication
Submission of Audited Financial Results along with Auditors Report.29 May 2026 · Result / Financial Results
The Board of Directors of the Company have approved the Audited Financial Results for the quarter and year ended March 31, 2026 at their meeting held on May 29, 2026.29 May 2026 · Board Meeting / Outcome of Board Meeting
Pharmaids Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Audited Financial ....22 May 2026 · Board Meeting / Board Meeting
Pursuant to the Regulation 24A of SEBI (LODR) Regulations, 2015, enclosed is the Annual Secretarial Compliance Report for the year ended March 31, 2026.8 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Newspaper publication regarding the Special Window open for Re-Lodgement of transfer deeds.24 Apr 2026 · Company Update / Newspaper Publication
Certificate under Regulation 74(5) of the SEBI (Depositaries and Participants) Regulations, 2018 for the quarter ended March 31, 2026.7 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Sale of entire shareholding held by Adita Bio Sys Private Limited (material subsidiary of the Company) in Siri Labvivo Diet Private Limited, a step-down subsidiary, resulting in cessation ....27 Mar 2026 · Company Update / General
Intimation of Trading Window Closure pursuant to declaration of Audited Financial Results for the quarter and Year ended March 31, 2026.25 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation under Regulation 30 of LODR.24 Feb 2026 · Company Update / General
Corrigendum to the newspaper publication dated February 14, 2026, regarding unaudited financial results (Consolidated and Standalone) for the quarter and nine months ended December 31, 2025.15 Feb 2026 · Company Update / Newspaper Publication
Newspaper Publication of unaudited financial results (Consolidated and Standalone) for the quarter and nine months ended December 31, 2025.14 Feb 2026 · Company Update / Newspaper Publication
Report of Auditors on Financial Results for the quarter and nine months ended December 31, 2025 with UDIN12 Feb 2026 · Company Update / General
Unaudited financial results for the quarter and nine months ended December 31, 202512 Feb 2026 · Result / Financial Results
Outcome of the Board Meeting held on Thursday, February 12, 2026, i.e, today, to consider and approve the un-audited financial results for the quarter and nine months ended December 31, 2025.12 Feb 2026 · Board Meeting / Outcome of Board Meeting
Pharmaids Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve the Unaudited Financial ....9 Feb 2026 · Board Meeting / Board Meeting
Report on shares re-lodged for transfer cum Demat of Physical shares.16 Jan 2026 · Company Update / General
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025.12 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation regarding completion of term of Independent Director of Mr. Mopperthy Sudheer5 Jan 2026 · Company Update / Change in Management
Outcome of the circular resolution dated January 05, 2026 for the reconstitution of the Audit and Nomination and Remuneration Committee of the Board.5 Jan 2026 · Company Update / General
This is to inform you that shareholders of the company have approved the appointment of Dr. Yogananda Moolemath (DIN: 02870387) as an Independent Director of the Company.2 Jan 2026 · Company Update / Change in Management
Please find enclosed scrutinizer''s report along with the proceedings of the meeting held by way of postal ballot through remote e-voting process.2 Jan 2026 · AGM/EGM / Postal Ballot

Board meetings

12 Aug 2026 Board Meeting - Financial Results